Çѱ¹ÀǾàÀü´Þ½Ã½ºÅÛÇÐȸ KCRS
home > ȸ¿ø°ø°£ > ÀÚ·á½Ç

ÀÚ·á½Ç

 

   
  Ãßõ»çÀÌÆ®ÈĽõòsites.google.com/view/gamblervia286Ãßõ»çÀÌ¡¦
  ±Û¾´ÀÌ : Ã÷ƼÆ÷     ³¯Â¥ : 22-09-01 01:08     Á¶È¸ : 126    
Ãßõ»çÀÌÆ®ÈĽõòsites.google.com/view/gamblervia286Ãßõ»çÀÌÆ®µµ¶õ»ç¹Î|À±¾Æ½ºÅ¸È­º¸ | ¸¶±×¹Ðjkl¤Õ
Ãßõ»çÀÌÆ®<- ¹Ù·Î°¡±â

GENEVA--( / ) June 20, 2017 -- Masimo (NASDAQ: MASI) announced today the findings of an abstract presented at Euroanaesthesia 2017 in Geneva, Switzerland. In the study, researchers at University Medical Center Groningen, Netherlands, compared original and Next Generation versions of Masimo Patient State Index (PSi, a processed EEG parameter related to the effect of anesthetic agents) during Masimo SedLine¢ç brain function monitoring of patients under propofol and sevoflurane anesthesia.[1]

SedLine brain function monitoring features four simultaneous EEG leads to enable continuous assessment of both sides of the brain, four EEG waveforms, a Density Spectral Array (DSA, an easy-to-interpret, high-resolution display of bi-hemispheric activity and EEG power), and PSi. Next Generation SedLine enhances PSi to make it less susceptible to electromyographic (EMG) interference and to improve its performance in low-power EEG cases.

In the study, Dr. Kuizenga and colleagues sought to compare the original and Next Generation PSi algorithms, referred to as PSi-1 and PSi-2, respectively, as they correlated with propofol and sevoflurane drug concentrations and with the Modified Observers Assessment of Alertness and Sedation (MOAAS) scale. They also sought to assess the influence of 2 and 4 ng/mL effect-site concentrations of remifentanil on the performance of the two algorithms.

The researchers enrolled 36 healthy volunteers, stratified by age, and assigned them randomly to a sequence of four sessions of anesthesia. In one session, propofol was administered in a series of graded steps; in the second, sevoflurane was similarly administered; in the third and fourth, the two concentrations of remifentanil were also administered. During each step of each session, after a twelve-minute delay for equilibration, MOAAS was tested and a blood sample was taken to measure drug concentrations. EEG was collected using Masimo Root¢ç with SedLine¢ç, from which time-synchronized PSi-1 and PSi-2 values were later extracted. The researchers then plotted MOAAS, drug concentration, PSi-1, and PSi-2 values over time.

The researchers found that when charted against drug concentrations, PSi-2 showed ¡°reduced population variability and improved baseline stability¡± compared to PSi-1. When charted against MOAAS, PSi-2 had ¡°lower interindividual variability¡± than PSi-1. They also noted that ¡°Both PSis distinguish MOAAS 5, 4, and 3 better during propofol anesthesia compared to sevoflurane. This difference disappears when adding remifentanil.¡±

The investigators concluded that ¡°PSi-2 [Next Generation SedLine PSi] has enhanced signal stability and a better descript-xion of the dose-response relationship. PSi-2 has therefore improved capacity as a pharmacodynamic monitor of anesthesia compared to PSi-1.¡±

Next Generation SedLine has not received FDA 510(k) clearance and is not available for sale in the United States.

Reference

[1] Kuizenga M.H., Colin P.J., Vereecke H.E.M., Struys M.M.R.F. Comparison between two versions of the Patient State Index during propofol and sevoflurane anesthesia, with or without remifentanil. Proceedings from Euroanaesthesia 2017, Geneva, Switzerland. Abstract #01AP07-4.

About Masimo

Masimo (NASDAQ: MASI) is a global leader in innovative noninvasive monitoring technologies. Our mission is to improve patient outcomes and reduce the cost of care. In 1995, the company debuted Masimo SET¢ç Measure-through Motion and Low Perfusion¢â pulse oximetry, which has been shown in multiple studies to significantly reduce false alarms and accurately monitor for true alarms. Masimo SET¢ç has also been shown to help clinicians reduce severe retinopathy of prematurity in neonates,[1] improve CCHD screening in newborns,[2] and, when used for continuous monitoring with Masimo Patient SafetyNet¢â* in post-surgical wards, reduce rapid response activations and costs.[3,4,5] Masimo SET¢ç is estimated to be used on more than 100 million patients in leading hospitals and other healthcare settings around the world,[6] and is the primary pulse oximetry at 16 of the top 20 hospitals listed in the 2016-17 U.S. News and World Report Best Hospitals Honor Roll.[7] In 2005, Masimo introduced rainbow¢ç Pulse CO-Oximetry technology, allowing noninvasive and continuous monitoring of blood constituents that previously could only be measured invasively, including total hemoglobin (SpHb¢ç), oxygen content (SpOC¢â), carboxyhemoglobin (SpCO¢ç), methemoglobin (SpMet¢ç), and more recently, Pleth Variability Index (PVi¢ç) and Oxygen Reserve Index (ORi¢â), in addition to SpO2, pulse rate, and perfusion index (PI). In 2014, Masimo introduced Root¢ç, an intuitive patient monitoring and connectivity platform with the Masimo Open Connect¢â (MOC-9¢â) interface, enabling other companies to augment Root with new features and measurement capabilities. Masimo is also taking an active leadership role in mHealth with products such as the Radius-7¢â wearable patient monitor, iSpO2¢ç pulse oximeter for smartphones, and the MightySat¢â fingertip pulse oximeter. Additional information about Masimo and its products may be found at Published clinical studies on Masimo products can be found at

*The use of the trademark Patient SafetyNet is under license from University HealthSystem Consortium.

References

[1] Castillo A et al. Prevention of Retinopathy of Prematurity in Preterm Infants through Changes in Clinical Practice and SpO2 Technology. Acta Paediatr. 2011 Feb;100(2):188-92.

[2] de-Wahl Granelli A et al. Impact of pulse oximetry screening on the detection of duct dependent congenital heart disease: a Swedish prospective screening study in 39,821 newborns. BMJ. 2009;338.

[3] Taenzer AH et al. Impact of Pulse Oximetry Surveillance on Rescue Events and Intensive Care Unit Transfers: A Before-And-After Concurrence Study. Anesthesiology. 2010; 112(2):282-287.

[4] Taenzer AH et al. Postoperative Monitoring - The Dartmouth Experience. Anesthesia Patient Safety Foundation Newsletter. Spring-Summer 2012.

[5] McGrath SP et al. Surveillance Monitoring Management for General Care Units: Strategy, Design, and Implementation. The Joint Commission Journal on Quality and Patient Safety. 2016 Jul;42(7):293-302.

[6] Estimate: Masimo data on file.

[7]

Forward-Looking Statements

This press release includes forward-looking statements as defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, in connection with the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, among others, statements regarding the potential effectiveness of Masimo SedLine¢ç. These forward-looking statements are based on current expectations about future events affecting us and are subject to risks and uncertainties, all of which are difficult to predict and many of which are beyond our control and could cause our actual results to differ materially and adversely from those expressed in our forward-looking statements as a result of various risk factors, including, but not limited to: risks related to our assumptions regarding the repeatability of clinical results; risks related to our belief that Masimo¡®s unique noninvasive measurement technologies, including Masimo SedLine, contribute to positive clinical outcomes and patient safety; as well as other factors discussed in the ¡°Risk Factors¡± section of our most recent reports filed with the Securities and Exchange Commission (¡°SEC¡±), which may be obtained for free at the SEC¡¯s website at Although we believe that the expectations reflected in our forward-looking statements are reasonable, we do not know whether our expectations will prove correct. All forward-looking statements included in this press release are expressly qualified in their entirety by the foregoing cautionary statements. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of today's date. We do not undertake any obligation to update, amend or clarify these statements or the ¡°Risk Factors¡± contained in our most recent reports filed with the SEC, whether as a result of new information, future events or otherwise, except as may be required under the applicable securities laws.

View source version on businesswire.com:Korea Newswire distributes your news across every media channels through the industry¡¯s largest press release distribution network

CORAL GABLES, FLA.--( / ) April 21, 2017 -- AerSale¢ç announced today that Basil Barimo has joined the organization as Chief Æ®¸®¸¶µ¹ CORALOfficer. In this role, Barimo will serve as a member of the senior ¶óÀ̺꽺ÄÚ¾î management team and be responsible for ÀÚ¿¬»ê ºñ¾Æ±×¶ó ¸¸µé±â CORALday-to-day global operations Ãßõ»çÀÌÆ® Çؿܽ¹«ÆÐ of AerSale, providing strategic leadership and oversight to assigned departments.



¡°As Ãßõ»çÀÌÆ® the breadth of our service and product offerings continues to expand, we determined that AerSale needs a Chief Operating Officer dedicated solely to day-to-day operations. We sought to strengthen our management team by adding an industry expert with an impressive track record ¶óÀ̺꽺ÄÚ¾î ÇÁ·Î¾ß±¸Áß°è to give us more depth and operational leadership to ¶óÀ̺꽺ÄÚ¾î 365bet execute on our growth strategy,¡± said Nicolas Finazzo, Chief Executive Officer of AerSale. ¡°Basil¡¯s Ãßõ»çÀÌÆ® ÇÏÅ°½ºÄÚ¾î experience in strategic execution and transforming company operations will make »ý¸®½Ä¿°¼ö ¡°Asa vital member of our team.¡±



With nearly three decades of ¶óÀ̺꽺ÄÚ¾î aviation experience driving complex organizations to deliver exceptional performance, Barimo is an Ãßõ»çÀÌÆ® ÀÎÆ÷»çÄ¿ influential and well-networked leader who has held senior management roles in public, private, and top industry trade organizations. His extensive scope of expertise includes ¾ßÅë Withand operations management, airline operational leadership, aerospace manufacturing, airline industry politics, and MRO marketing and ¶óÀ̺꽺ÄÚ¾î pricing strategies. Barimo was most recently Executive Vice Ãßõ»çÀÌÆ® °í¾×¹èÅÍÀÇ À§¾ö President, Repair Group for the NORDAM Group, and previously À§·Ê¼ºÀοëÇ°Ãßõ Withas Vice President of Operations and Safety for the Air Transport ¼ö³²¼ºÅ¬¸®´Ð Withof America, Vice President of Operations for Avborne, Inc., and Senior Director of Maintenance Quality Assurance at US Airways.



AerSale co-founder Robert Nichols, who has been the Ãßõ»çÀÌÆ® company¡¯s Chief ¶óÀ̺꽺ÄÚ¾î ´ÔÀº¸Õ°÷¿¡ Operating Officer since inception, stated: ¡°The size and ¶óÀ̺꽺ÄÚ¾î ½á´ÏÇ¥Á¤ complexity of AerSale¡¯s day-to-day operations now requires so much of my time that »¡°£µüÁö AerSalehave been ¶óÀ̺꽺ÄÚ¾î ¸Æ½Éºª unable to focus on building the business, which is my primary role as one of the principal founders. With Basil running day-to-day, I can now refocus on scaling the business, strategic partnerships, business development, acquisitions, executive recruiting, and global strategy.¡±



A global aviation leader, Ãßõ»çÀÌÆ® AerSale supplies aftermarket commercial aircraft, engines, and OEM used ¶óÀ̺꽺ÄÚ¾î serviceable material to passenger and cargo airlines, leasing organizations, government entities, ¶óÀ̺꽺ÄÚ¾î °­¿ø·£µå½½·Ô¸Ó½Å multinational OEMs, and independent MROs. AerSale also °ü°íµ¿¼ºÀΰÔÀÓÀå Aasset management services to owners of end-of-life aircraft and engine portfolios. Headquartered in Coral Gables, Florida, AerSale maintains offices ¶óÀ̺꽺ÄÚ¾î and operations in the Ãßõ»çÀÌÆ® 3¸¸²Ç United States, Ãßõ»çÀÌÆ® Àå¾Ö¿ì±ÇÀ͹®Á¦¿¬±¸¼Ò Europe, and Asia.



ODVeAR Formore ¶óÀ̺꽺ÄÚ¾î information, visit or contact AerSale ±è·®À嵿¸Â°í ForÃßõ»çÀÌÆ® °­¿ø·£µåºí·¢Àè Relations by calling (305) 764-3200 or via Ãßõ»çÀÌÆ® ½Å²Ç ¾È¼ºÈ­ÅõÄ¡±â Forat media.relations@aersale.com.



View source version on businesswire.com:Korea °æ¾Ïµ¿È¦´ý´ëȸ Viewdistributes your ¶óÀ̺꽺ÄÚ¾î ÅäÅ乫·á¸Ó´Ï »ö½º Viewacross every media channels through the industry¡¯s largest press release distribution network Ãßõ»çÀÌÆ® µ¿¹æ½Å±âÆÒÇÈÇØÇÇÅõ°Ô´õ



¾î´úÆ®,Å䷻Ʈº½,ȣȣÅ÷,ĹÅ÷,ÇÁ¸®¹Ì¾ö19,ŸīÇϽüîÄÚ,Á¤¼±Ä«Áö³ëÃßõ,Àç¹ÌÀִº¹ºÒº¹°ÔÀÓ,©¹ðÅ©,¹ÌÆÃ,¶óÀ̺꽺ÄÚ¾î,¶óÀ̺꽺ÄÚ¾î,Åäºñ¾Æ,»óÆÄ¿ï·çFC,youav,¾ß¸¶Åä2°ÔÀÓµ¿¿µ»ó,¼¼¸®¿¡¸Å´Ï¾Æ,¼¼¸®¿¡¸Å´Ï¾Æ,¼¼¸®¿¡¸Å´Ï¾Æ,¼­¸®³ª,¿¡·Îƽ,Æļ¼Å¸ÁÖ,¾Æ½ºÇǸ° ºñ¾Æ±×¶ó,Á¤·Îȯ,¿Àºü´Þ·Á,ÆíÀÇÁ¡Äܵ¼Ãßõ,¶ó¶óƼºñ,¼½½º³ë¸®,°Ë»êµ¿¼ºÀΰÔÀÓÀå,HmDu,¿ªºÏµ¿¸Â°í,ºÎ»êµ¿È­ÅõÄ¡±â,±¸¾Ïµ¿È¦´ý´ëȸ,¼ºÀκñµð¿À,Åä¿ùµå,¾Ë¹ÙÆä¾î,¹ãÅ÷½º,°í18,Ç϶ó»ç¿À¸®,°­¿ø·£µå¹ÙÄ«¶óÁÖ¼Ò,ÀÎÅͳݺ¹ºÒº¹°ÔÀÓ,ÁÖ¼Òüũ,¹ÌÆþîÇÃ,¹ÌÆÃ,¹ÌÆÃ,¸ÔƢȸ´ã,IndependienteRivadavia,javtc,¾ß¸¶Åä3µ¿¿µ»ó,ÇØ¿ÜÃ౸,ÇØ¿ÜÃ౸